The effect of voglibose on metabolic profiles in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of clinical trials

被引：8

作者：

Nowrouzi-Sohrabi, Peyman ^{[1
]}

Tabrizi, Reza ^{[2
]}

Rezaei, Shahla ^{[3
]}

Jafari, Fatemeh ^{[2
]}

Hessami, Kamran ^{[4
]}

Abedi, Mehdi ^{[5
]}

Jalali, Mohammad ^{[6
]}

Keshavarzi, Pedram ^{[2
]}

Shahabi, Saeed ^{[2
]}

Kolahi, Ali Asghar ^{[7
]}

Carson-Chahhoud, Kristin ^{[8
]}

Sahebkar, Amirhossein ^{[9
,10
,11
]}

Safiri, Saeid ^{[12
,13
,14
]}

机构：

[1] Shiraz Univ Med Sci, Student Res Comm, Dept Biochem, Shiraz, Iran

[2] Shiraz Univ Med Sci, Inst Hlth, Hlth Policy Res Ctr, Shiraz, Iran

[3] Shiraz Univ Med Sci, Student Res Comm, Sch Nutr & Food Sci, Shiraz, Iran

[4] Shiraz Univ Med Sci, Student Res Comm, Maternal Fetal Med Res Ctr, Shiraz, Iran

[5] Shiraz Univ Med Sci, Sch Pharm, Dept Pharmaceut Nanotechnol, Shiraz, Iran

[6] Shiraz Univ Med Sci, Student Res Comm, Nutr Res Ctr, Shiraz, Iran

[7] Shahid Beheshti Univ Med Sci, Social Determinants Hlth Res Ctr, Tehran, Iran

[8] Univ South Australia, Sch Hlth Sci, Australian Ctr Precis Hlth, Adelaide, SA, Australia

[9] FDA, Halal Res Ctr IRI, Tehran, Iran

[10] Mashhad Univ Med Sci, Pharmaceut Technol Inst, Biotechnol Res Ctr, Mashhad, Razavi Khorasan, Iran

[11] Mashhad Univ Med Sci, Neurogen Inflammat Res Ctr, Mashhad, Razavi Khorasan, Iran

[12] Tabriz Univ Med Sci, Sch Med, Dept Community Med, Social Determinants Hlth Res Ctr, Tabriz, Iran

[13] Univ Tehran Med Sci, Neurosci Inst, Sports Med Res Ctr, Tehran, Iran

[14] Tabriz Univ Med Sci, Aging Res Inst, Phys Med & Rehabil Res Ctr, Tabriz, Iran

来源：

PHARMACOLOGICAL RESEARCH | 2020年 / 159卷

关键词：

Voglibose; Diabetes mellitus; Metabolic profiles; Meta-analysis; ALPHA-GLUCOSIDASE INHIBITORS; INSULIN SENSITIVITY; JAPANESE PATIENTS; EFFICACY; ADIPONECTIN; SAFETY; ACARBOSE; ATHEROSCLEROSIS; DYSLIPIDEMIA; PIOGLITAZONE;

D O I：

10.1016/j.phrs.2020.104988

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Objective: The effect of voglibose on metabolic homeostasis is not well characterized. Therefore, we conducted a systematic review and meta-analysis of clinical trials assessing the effect of voglibose on metabolic profile in patients with type 2 diabetes mellitus (T2DM). Methods: Systematic searches were conducted in PubMed, Scopus, Embase, Google Scholar, Web of Science and Cochrane Library to identify clinical trials assessing the effects of voglibose supplementation on cardio-metabolic profile from incept up to 29 July 2019. Data was pooled using fixedor random-effect models and weighted mean difference (WMD) as the effect size. Results: Eight clinical trials from 1094 reports, were eligible for inclusion. Pooled findings identified significant reductions in hemoglobin A1c (HbA1c) (WMD= -0.27; 95 %CI -0.49 to -0.05; P = 0.01; I-2 = 64.8 %) and an increase in LDL-cholesterol levels (WMD=5.97 mg/dl, 95 % CI 0.88, 11.06, P = 0.02; I-2 = 0.0 %). However, no evidence of effect for voglibose intake on T2DM patients was observed for: fasting blood sugar (FBS) (WMD - 7.43 mg/dl; 95 %CI-16.56 to 1.71; P = 0.110; I-2 = 69.3 %), serum insulin (WMD= -0.15 mu U/mL; 95 %CI - 0.89 to 0.60; P = 0.70; I-2 = 0.0 %), total-cholesterol (WMD=2.82 mg/dl, 95 %CI-2.36 to 8.01, P = 0.70; I-2 = 49.7 %), triglycerides (WMD= -7.07 mg/dl, 95 %CI -21.76 to 7.62, P = 0.34; I-2 = 0.0 %), HDL-cholesterol levels (WMD= -2.10 mg/dl, 95 %CI -4.48 to 0.27, P = 0.08; I-2 = 0.0 %,), body mass index (BMI) (WMD=0.09 kg/m(2), 95 %CI -0.70 to 0.87; P = 0.87; I-2 = 0.0 %), body weight (WMD= -0.42 kg, 95 %CI - 0.84 to 0.00; P = 0.05; I-2 = 0.0 %), and adiponectin levels (WMD = 0.32 mu g/mL, 95 %CI -0.74 to 1.38; P = 0.55; I-2 = 0.0 %). Conclusions: The current meta-analysis identified a decrease in HbA1c and an increase in LDL-cholesterol with administration of voglibose. However, no significant effect was observed on FBS, insulin, bodyweight, BMI, adiponectin, triglycerides, totaland HDL-cholesterol levels.

引用

页数：7

共 37 条

[1] Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction [J].